If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Trulicity ® (dulaglutide) injection
0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3mg/0.5mL, 4.5mg/0.5mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
How should Trulicity® (dulaglutide) be injected?
Dulaglutide should be injected subcutaneously in the abdomen, thigh, or upper arm.
See important safety information, including boxed warning, in the attached prescribing information.
Route of Administration
Dulaglutide should be injected subcutaneously in the abdomen, thigh, or upper arm.1
Injection site location does not affect dulaglutide exposure; therefore, dulaglutide may be administered in the abdomen, thigh, or upper arm without adjusting the dose.2
Other Administration Locations
Eli Lilly and Company has not sponsored any clinical studies evaluating the subcutaneous injection of dulaglutide in locations other than the abdomen, thigh, or upper arm.2
Intravenous or Intramuscular Administration
Dulaglutide is not approved to be injected intravenously or intramuscularly.1
Enclosed Prescribing Information
References
1Trulicity [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.
2Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: July 12, 2022